Adult heights attained by children with hypothalamic/chiasmatic glioma treated with growth hormone.
Hypothalamic/chiasmatic gliomas (H/CG) in children are commonly accompanied by endocrine dysfunction due to mass effects of the tumor itself or as a consequence of tumor therapy, with GH deficiency (GHD) being the most common disorder. We report the height outcomes of GH-treated H/CG patients with GHD. We reviewed the records of 14 GHD patients with H/CG who were treated with human GH. A comparison group of non-GH-treated H/CG patients was also identified. Heights were expressed as sd scores (SDS). For GH-treated patients, the mean initial height was -0.7 +/- 0.3 (+/-se). Their mean final height was -0.3 +/- 0.3. The mean change in height SDS for the GH-treated group was +0.4. The mean initial and final height SDS for the non-GHD patients were 0.6 (se = 0.4) and 0.0 (se = 0.4), respectively. The mean change in height SDS was -0.6. The GHD patients had significantly lower initial height SDS compared with the non-GHD patients (P = 0.01) and had a significantly greater change in their height SDS (P = 0.04). GH treatment for H/CG patients restores much of their growth potential and improves adult height to within normal limits.
Kim
Roy J
RJ
Division of Endocrinology, Department of Pediatrics, University of Pennsylvania School of Medicine and Children's Hospital of Philadelphia, Philadelphia, Pennsylvania 19104, USA.
Janss
Anna
A
Shanis
Dana
D
Homan
Sarah
S
Moshang
Thomas
T
D000293:Adolescent; D000328:Adult; D001827:Body Height / Q000187:drug effects*; D016208:Databases, Factual; D005260:Female; D005910:Glioma / Q000188:drug therapy*; D019382:Human Growth Hormone / Q000627:therapeutic use*; D006801:Humans; D007029:Hypothalamic Neoplasms / Q000188:drug therapy*; D008297:Male; D009897:Optic Chiasm
D019382:Human Growth Hormone